🇺🇸 FDA
Patent

US 11596633

SHP2 inhibitor compositions and methods for treating cancer

granted A61KA61K31/282A61K31/4427

Quick answer

US patent 11596633 (SHP2 inhibitor compositions and methods for treating cancer) held by Revolution Medicines, Inc. expires Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Revolution Medicines, Inc.
Grant date
Tue Mar 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K31/282, A61K31/4427, A61K31/4439, A61K31/497